Mosanna Therapeutics has successfully raised $80 million in Series A funding to advance its treatment for obstructive sleep apnea (OSA), primarily through the development of its product MOS118. The investment was led by Pivotal bioVenture Partners and EQT Life Sciences, among others. This capital will help propel MOS118 into Phase 2 clinical trials and broaden Mosanna's product pipeline. Additionally, the company appointed Dr. David Weber as CEO, enhancing its leadership with his extensive biotech experience. Investors see the unique nasal spray application method as a groundbreaking approach for improving patients’ lives suffering from OSA.
This is a great achievement by the Mosanna team! As investors since the seed round and in this Series A, we are excited to see MOS118 advance into the clinical stage. The simple mode of application via a nasal spray has the potential to drastically improve the life of patients suffering from sleep apnea.
Mosanna is taking a truly transformational approach to sleep apnea treatment - offering a non-invasive, non-mechanical solution designed to provide a better quality of life.
Collection
[
|
...
]